selected scholarly activity
-
chapters
-
conferences
- EVALUATING PATIENT PREFERENCES OF MAINTENANCE THERAPY FOR THE TREATMENT OF COPD: A DISCRETE CHOICE EXPERIMENT. Chest. 769A-769A. 2018
- Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD. European Respiratory Journal. 2018
- Economic and quality of life consequences of clinically important deterioration in patients with COPD: results from the TORCH study. European Respiratory Journal. 2018
- Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain. European Respiratory Journal. 2018
- Late Breaking Abstract - IMPACT study - single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs - UK. European Respiratory Journal. 2018
- Qualitative research evaluating patient preferences for a new COPD treatment. European Respiratory Journal. 2018
- Budget Impact of Adding a New Single Inhaler Triple Therapy (SITT) for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) in the UK. Value in Health. S232-S233. 2018
- Cost-Effectiveness of a Single Inhaler Triple Therapy vs a Dual Inhaled Corticosteroid Plus Long-Acting Beta Agonist (ICS/LABA) for Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom (UK). Value in Health. S234-S234. 2018
- Cost-Minimization Analysis of Adding a New Single Inhaler Triple Therapy (SITT) for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (Copd) in the UK. Value in Health. S235-S235. 2018
- Economic Consequences of Clinically Important Deterioration in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the Torch Study. Value in Health. S233-S233. 2018
- Long-Term Consequences of Clinically Important Deterioration in Patients with Chronic Obstructive Pulmonary Disease Treated with Twice-Daily Inhaled Corticosteroid/Long-Acting beta 2-Agonist Therapy: Results from the TORCH Study. American Journal of Respiratory and Critical Care Medicine. 2018
- Economic Evaluation of Single Inhaler Triple Therapy For Patients With Chronic Obstructive Pulmonary Disease (COPD) Using The Galaxy Model. Value in Health. A646-A646. 2017
- Health and Economic Benefits of Using Single Versus Multiple Inhalers in Patients with Asthma: A Systematic Literature Review. Value in Health. A575-A575. 2017
- Single Versus Multiple Inhalers in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. Value in Health. A574-A574. 2017
- Cost effectiveness of umeclidinium bromide 62.5μg plus ICS/LABA versus ICS/LABA in COPD. European Respiratory Journal. 2017
- Cost impact of time to initiation of triple therapy in COPD patients in Japan: A retrospective analysis of healthcare claims data. European Respiratory Journal. 2017
- Cost-effectiveness of umeclidinium bromide 62.5µg or alternative LAMA plus ICS/LABA in COPD. European Respiratory Journal. 2017
- Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study. European Respiratory Journal. 2017
- The cost burden of COPD in France: A retrospective analysis of an administrative primary care database. European Respiratory Journal. 2017
- Treatment patterns of COPD patients in France: A retrospective analysis of an administrative primary care healthcare database. European Respiratory Journal. 2017
- COST-EFFECTIVENESS ANALYSES OF UMECLIDINIUM BROMIDE 62.5 MCG VERSUS GLYCOPYRRONIUM 44 MCG AND UMECLIDINIUM BROMIDE 62.5 MCG VERSUS TIOTROPIUM 18 MCG IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UK. Value in Health. A202-A202. 2017
- The Impact of Adherence and Exacerbation Frequency on Health Care Utilization and Associated Direct Costs in Severe Asthma. Chest. 827A-827A. 2016
- Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis. European Respiratory Journal. 2016
- The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD. European Respiratory Journal. 2016
- Some Statistical Considerations in Estimating a Disease Progression Model for Chronic Obstructive Pulmonary Disease (COPD). Pharmacoepidemiology and Drug Safety. 624-625. 2016
- Comparative Assessment Of Umeclidinium/vilanterol (umec/vi) Combination Therapy Among Symptomatic Patients With COPD. American Journal of Respiratory and Critical Care Medicine. 2016
- Comparative Efficacy Of Umeclidinium Versus Other Long-Acting Muscarinic Antagonist In Combination With Ics/laba. American Journal of Respiratory and Critical Care Medicine. 2016
- Direct Cost-Of-Illness Study Of Asthma In Quebec. American Journal of Respiratory and Critical Care Medicine. 2016
- The Burden Of Illness Related To COPD Exacerbations In Quebec, Canada. American Journal of Respiratory and Critical Care Medicine. 2016
- The Morbidity, Mortality, And Healthcare Utilization Attributed To Cardiovascular Disease In COPD Patients In Quebec, Canada. American Journal of Respiratory and Critical Care Medicine. 2016
- Comparative Assessment Of Umeclidinium Bromide In Combination With Fluticasone Propionate/salmeterol Among Symptomatic COPD Patients. American Journal of Respiratory and Critical Care Medicine. 2015
- Comparative Efficacy Of Umeclidinium/vilanterol Versus Other Lama/laba As Maintenance Treatments For COPD: A Systematic Review And Network Meta-Analysis. American Journal of Respiratory and Critical Care Medicine. 2015
- Does Lung Function Change Correlate With Patient Reported Outcomes (pros) In Stable Chronic Obstructive Pulmonary Disease (COPD)?. American Journal of Respiratory and Critical Care Medicine. 2015
- Budget Impact Analysis Of Dolutegravir In The Treatment Of Human Immunodeficiency Virus (Hiv) In Ontario, Canada. Value in Health. A269-A269. 2014
- Real World Drug Utilization Of Hiv Therapies In Canada. Value in Health. A281-A281. 2014
- Some statistical considerations in estimating a disease progression model for chronic obstructive pulmonary disease (COPD). Value in Health. A183-A183. 2014
- Modeling a Switch from Trivalent to Quadrivalent Influenza Vaccine in Canada and the United Kingdom. Value in Health. A586-A586. 2013
- Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study. European Respiratory Journal. 2013
- A cost-minimization analysis of a new fixed-dose combination of dutasteride and tamsulosin compared to concomitant administration of both monotherapies for the treatment of symptomatic benign prostatic hyperplasia in Quebec, Canada. Value in Health. A182-A182. 2013
- Costs and health care resource utilization associated with asthma in canada: A systematic review. Value in Health. A188-A188. 2013
- PIH12 Budget Impact Analysis of Adding a New Fixed-Dose Combination Therapy of Dutasteride and Tamsulosin to the Treatment of Symptomatic Benign Prostatic Hyperplasia in Quebec, Canada. Value in Health. A193-A193. 2012
- PIH16 Cost-Effectiveness of a New Fixed-Dose Combination of Dutasteride and Tamsulosin for the Treatment of Symptomatic Benign Prostatic Hyperplasia in Quebec, Canada. Value in Health. A194-A194. 2012
- PIH27 Potential Health and Economic Impact of Adding Rotarixtm to Routine Infant Vaccination Programs in Canada. Value in Health. A402-A402. 2011
- Observational study of the temporal trends in use of percutaneous coronary intervention and coronary artery bypass surgery associated with acute myocardial infarction in Canada, 2002-2009. European Heart Journal. 1049-1049. 2011
- PROVINCIAL VARIATION IN HOSPITALIZATION EVENT RATES AND MORTALITY ASSOCIATED WITH ACUTE MYOCARDIAL INFARCTION IN CANADA: A SYSTEMATIC LITERATURE REVIEW. Canadian Journal of Cardiology. 31D-31D. 2010
- PIN14 REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COST-CONSEQUENCE ANALYSIS OF A 7-, 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CANADA. Value in Health. A188-A188. 2010
- PIN33 POTENTIAL HEALTH AND ECONOMIC IMPACT OF NEW PNEUMOCOCCAL VACCINES IN CANADA: A MARKOV MODELLING APPROACH. Value in Health. A423-A423. 2009
- PIN8 BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA. Value in Health. A418-A418. 2009
- PIH9 A SIMULATION MODELING OF THE EFFECT OF DOSING SCHEDULE ON THE BENEFIT AND COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION IN CANADA. Value in Health. A163-A163. 2009
- PSS2 DISTRIBUTION OF PATHOGENS ASSOCIATED WITH ACUTE OTITIS MEDIA: A SYSTEMATIC REVIEW OF THE LITERATURE. Value in Health. A75-A75. 2009
- PSS9 REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COSTCONSEQUENCE ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) COMPARED WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7). Value in Health. A76-A76. 2009
- VA2 COST EFFECTIVENESS ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN CANADA. Value in Health. A9-A9. 2009
- Statistical issues in the design and analysis of expertise‐based randomized clinical trials. Statistics in Medicine. 6583-6596. 2008
-
journal articles
- Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respiratory Research. 25:152. 2024
- Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. BMJ Open. 14:e072361-e072361. 2024
- Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany. International Journal of COPD. Volume 19:945-956. 2024
- Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach. Advances in Therapy. 40:4689-4690. 2023
- DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach. Advances in Therapy. 40:4282-4297. 2023
- Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respiratory Research. 24:229. 2023
- A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”. Advances in Therapy. 40:2556-2561. 2023
- Correction to: A tutorial on pilot studies: the what, why and how. BMC Medical Research Methodology. 23:59. 2023
- Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study. International Journal of COPD. Volume 18:2933-2953. 2023
- Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review. International Journal of COPD. Volume 18:719-731. 2023
- COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. International Journal of COPD. Volume 18:407-418. 2023
- Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England. International Journal of COPD. Volume 18:2039-2054. 2023
- Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. International Journal of COPD. Volume 18:643-659. 2023
- Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England. International Journal of COPD. Volume 18:1431-1444. 2023
- Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK. International Journal of COPD. Volume 18:1815-1825. 2023
- Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK. International Journal of COPD. Volume 18:2673-2685. 2023
- Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. International Journal of COPD. Volume 18:231-245. 2023
- Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in Therapy. 39:4961-5010. 2022
- Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in Therapy. 39:5011-5012. 2022
- Modeling the Health and Economic Burden of Chronic Obstructive Pulmonary Disease in China From 2020 to 2039: A Simulation Study. Value in Health Regional Issues. 32:8-16. 2022
- Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β2-agonist dual therapy in a primary care setting in England. BMJ Open Respiratory Research. 9:e001243-e001243. 2022
- Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Advances in Therapy. 39:3957-3978. 2022
- Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam. Journal of Asthma. 59:1213-1220. 2022
- Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation. International Journal of COPD. Volume 17:491-504. 2022
- Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. International Journal of COPD. Volume 17:1455-1466. 2022
- Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England. International Journal of COPD. Volume 17:1781-1795. 2022
- Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain. International Journal of COPD. Volume 17:2161-2174. 2022
- Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. International Journal of COPD. Volume 17:2417-2429. 2022
- Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial. International Journal of COPD. Volume 17:3097-3109. 2022
- Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial. International Journal of COPD. Volume 17:2745-2755. 2022
- Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. International Journal of COPD. Volume 17:415-426. 2022
- Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Research. 8:00333-2021. 2022
- Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. International Journal of COPD. Volume 17:1633-1642. 2022
- INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Research. 7:00950-2020. 2021
- Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD. Volume 16:3105-3118. 2021
- Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. International Journal of COPD. Volume 16:2591-2604. 2021
- Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England. International Journal of COPD. Volume 16:2795-2808. 2021
- Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. International Journal of COPD. Volume 16:1255-1264. 2021
- Treatment Preferences of Patients with Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups in the United Kingdom, United States, and Germany. Chronic Obstructive Pulmonary Diseases. 8:19-30. 2021
- <p>Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective</p>. International Journal of COPD. Volume 15:1621-1632. 2020
- <p>Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review</p>. International Journal of COPD. Volume 15:439-460. 2020
- <p>Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and Germany</p>. International Journal of COPD. Volume 15:595-604. 2020
- <p>Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review</p>. International Journal of COPD. Volume 15:417-438. 2020
- Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design. ERJ Open Research. 5:00061-2019. 2019
- Direct and indirect costs associated with moderate and severe asthma in Quebec, Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 3:134-142. 2019
- <p>Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial</p>. International Journal of COPD. Volume 14:2681-2695. 2019
- <p>Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease</p>. International Journal of COPD. Volume 14:2121-2129. 2019
- <p>Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study</p>. International Journal of COPD. Volume 14:939-951. 2019
- COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners. International Journal of COPD. Volume 14:51-63. 2019
- Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective. Respiratory Medicine: X. 1:100008-100008. 2019
- Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. Respiratory Medicine. 145:130-137. 2018
- Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation. 16:17. 2018
- Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respiratory Research. 19:19. 2018
- Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Research. 4:00047-2018. 2018
- A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD. Pulmonary Therapy. 3:297-316. 2017
- Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial. Advances in Therapy. 34:2163-2172. 2017
- Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. Medical decision making. 37:469-480. 2017
- Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. Medical decision making. 37:453-468. 2017
- The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada. Canadian Respiratory Journal. 2017:1-10. 2017
- Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review. BMC Research Notes. 8:464. 2015
- Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infectious Diseases. 15:465. 2015
- Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK. Cost Effectiveness and Resource Allocation. 13:22. 2015
- Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. International Journal of COPD. 10:1863-1863. 2015
- Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. International Journal of COPD. 10:2495-2495. 2015
- Comparative Efficacy of Umeclidinium Bromide Versus Other Long-Acting Anticholinergic Monotherapies as Treatments for Copd Patients. Value in Health. 17:A588-A589. 2014
- Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients. Value in Health. 17:A595-A595. 2014
- Cost-Effectiveness Analysis of Umeclidinium Bromide Compared to Tiotropium Bromide for Symptomatic Patients with COPD in the UK. Value in Health. 17:A595-A595. 2014
- Validating A Model To Predict Disease Progression Outcomes In Patients With COPD. Value in Health. 17:A560-A561. 2014
- COST-effectiveness of salmeterol/fluticasone propionate combination (Advair®) in uncontrolled asthma in Canada. Respiratory Medicine. 108:1292-1302. 2014
- Understanding worker–parent engagement in child protection casework. Children and Youth Services Review. 44:56-64. 2014
- Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients. Current Medical Research and Opinion. 30:1417-1425. 2014
- Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Current Medical Research and Opinion. 30:1427-1436. 2014
- Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada. Journal of the Canadian Urological Association. 8:1-1. 2014
- Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. BMC Pulmonary Medicine. 13:70. 2013
- Clinical experience may affect clinician compliance with assigned treatment in randomized trials. Journal of Clinical Epidemiology. 66:768-774. 2013
- The aging Canadian population and hospitalizations for acute myocardial infarction: projection to 2020. BMC Cardiovascular Disorders. 12:25. 2012
- Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial. Journal of the Canadian Urological Association. 6:1-9. 2012
- Ratings of counterproductive performance: the effect of source and rater behavior. International Journal of Productivity and Performance Management. 61:142-156. 2012
- Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. Journal of Medical Economics. 15:61-76. 2012
- Looking at engagement and outcome from the perspectives of child protection workers and parents. Children and Youth Services Review. 34:112-118. 2012
- Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of Clinical Epidemiology. 64:1187-1197. 2011
- A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine. 28:G3-G13. 2010
- Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: A multicountry analysis. Vaccine. 28:G14-G22. 2010
- AHRQ Series Paper 4: Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. Journal of Clinical Epidemiology. 63:502-512. 2010
- A tutorial on pilot studies: the what, why and how. BMC Medical Research Methodology. 10:1. 2010
- Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. ACP journal club. 148:379-379. 2008
- Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: A systematic review. Clinical Biochemistry. 41:250-259. 2008
- Evidence for the use of B-type natriuretic peptides for screening asymptomatic populations and for diagnosis in primary care. Clinical Biochemistry. 41:240-249. 2008
- Patient Views on Reminder Letters for Influenza Vaccinations in an Older Primary Care Patient Population. Canadian Journal of Public Health. 99:133-136. 2008
- Brain type carnosinase in dementia: a pilot study. BMC Neurology. 7:38. 2007
- Comparison of Bayesian and frequentist approaches in modelling risk of preterm birth near the Sydney Tar Ponds, Nova Scotia, Canada. BMC Medical Research Methodology. 7:39. 2007
- Understanding linear and logistic regression analyses. Canadian Journal of Emergency Medicine. 9:111-113. 2007
- Elevated Cardiac Troponin Measurements in Critically Ill Patients. JAMA Internal Medicine. 166:2446-2446. 2006
- Screening for hypoglycemia at the bedside in the neonatal intensive care unit (NICU) with the Abbott PCx glucose meter. BMC Pediatrics. 6:28. 2006